Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics Ltd., a life sciences company, is conducting a study on Bucillamine for treating nerve agent exposure and exploring its potential against viral infections like Mpox. Bucillamine, a known rheumatoid arthritis treatment, may also offer benefits in easing Mpox symptoms due to its potent antioxidant properties, though no claims are made about its efficacy in treating infectious diseases at this stage.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
